CHA₂DS₂-VASc
Qiimeynta Khatarta Thromboembolic-ka ee Atrial Fibrillation
Natiijada
Fasiraadda
Dhibcaha CHA₂DS₂-VASc waxay qiyaasaan khatarta sanadka ah ee kiharuska bukaannada atrial fibrillation aan valvular-ka ahayn qaba. Talada anticoagulation waxaa lagu kala saaraa jinsiga: raga, waxaa la tixgeliyaa laga bilaabo 1 dhibcood; dheddigga, laga bilaabo 2 dhibcood — sababtoo ah 1 dhibcood oo si gaar ah lagu helay jinsiga dheddigga awgiis kuma filna khatar gaar ah oo ay ku baahan tahay anticoagulation.
| Dhibcaha | Khatarta kiharuska sanadka* | Talo (rag) | Talo (dumar) |
|---|---|---|---|
| 0 | 0% | Anticoagulation looma baahna | — |
| 1 | 1.3% | Tixgeli anticoagulation† | Looma baahna (1 dhibcood oo jinsiga uun ka yimid) |
| 2 | 2.2% | Waxaa lagu talinayaa anticoagulation | Tixgeli anticoagulation† |
| 3 | 3.2% | Waxaa lagu talinayaa anticoagulation | Waxaa lagu talinayaa anticoagulation |
| 4 | 4.0% | Waxaa lagu talinayaa anticoagulation | Waxaa lagu talinayaa anticoagulation |
| 5 | 6.7% | Waxaa lagu talinayaa anticoagulation | Waxaa lagu talinayaa anticoagulation |
| 6 | 9.8% | Waxaa lagu talinayaa anticoagulation | Waxaa lagu talinayaa anticoagulation |
| 7 | 9.6% | Waxaa lagu talinayaa anticoagulation | Waxaa lagu talinayaa anticoagulation |
| 8 | 6.7% | Waxaa lagu talinayaa anticoagulation | Waxaa lagu talinayaa anticoagulation |
| 9 | 15.2% | Waxaa lagu talinayaa anticoagulation | Waxaa lagu talinayaa anticoagulation |
* Khatarta la hagaajiyay ee ku salaysan Lip et al., 2010 (Euro Heart Survey cohort). Qiyaasaha waa ku kala duwan yihiin kooxaha iyo dadyowga kala duwan.
† Go'aan shakhsi ahaaneed oo ku salaysan khatarta dhiig-baxa (HAS-BLED) iyo doorbidka bukaanka. Hage-yaasha ESC 2020 iyo ACC/AHA 2023.
Xaalada caafimaad: Anticoagulation waa in la sameeyaa si shakhsi ahaaneed, iyada oo la tixgelinayo isku-dheelitirka khatarta-faa'iidada, iyadoo la eegayo khatarta dhiig-baxa (oo lagu qiimeeyo Dhibcaha HAS-BLED) iyo doorbidka bukaanka. Anticoagulant-yada afka lagu qaato ee toosan (DOACs) ayaa loo doorbidayaa marka la barbardhigo vitamin K antagonists atrial fibrillation-ka aan valvular-ka ahayn, ilaa haddii aysan jirin caqabad gaar ah. Fiiro gaar ah: Hage-yaasha ESC 2024 waxay soo bandhigeen dhibcaha CHA₂DS₂-VA (aan lahayn qaybta jinsiga dheddigga), iyaga oo dooddaya in jinsiga dheddigga uusan ahayn arrimo khatar madaxbanaan oo ku filan. Hage-yaasha ACC/AHA weli waxay isticmaalaan CHA₂DS₂-VASc ee dhaqan-galka ah. Labada habba way jiraan dhaqanka caafimaadka ee hadda.
Ogeysiis: Isticmaalka kalkuleytarkan waa bilaash. Si kastaba ha ahaatee, go'aannada caafimaad ee ku salaysan natiijooyinka waa in dhakhtarka mas'uulka ka ah daryeelka bukaanka uu ka fikiraa oo qaataa. Go'aammada aan habboonayn waxay soo dedejin karaan khataro caafimaad oo halis ah.
Ilaha
- 1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation." Chest. 2010;137(2):263–272. PubMed ↗
- 2. Hindricks G, Potpara T, Dagres N, et al. "2020 ESC Guidelines for the diagnosis and management of atrial fibrillation." Eur Heart J. 2021;42(5):373–498. PubMed ↗